Stock Price, News, Quote and Profile of DERMATA THERAPEUTICS INC(NASDAQ:DRMA) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

DERMATA THERAPEUTICS INC

NASDAQ:DRMA (12/18/2024, 8:14:38 PM)

After market: 1.04 0 (0%)

1.04

-0.06 (-5.45%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-59.37%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.12M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

Short Float %

Short Ratio

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Dermata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.